## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-8.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($95.58)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Incyte’s Tafasitamab Extension Study: A Boost for Hematologic Malignancies Treatment**
- Source: MSN | 20251130T173624 | Bullish | Relevance: 99%
- Incyte (INCY) announced significant positive results from the final analysis of its long-term extension study of tafasitamab, an antibody-drug conjugate. The study, conducted in partnership with MorphoSys, demonstrated sustained and clinically meaningful responses for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tafasitamab continues to show a well-tolerated safety profile consistent with previous findings, reinforcing its importance as a treatment option.

**2. Incyte Corp. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170600 | Neutral | Relevance: 98%
-  Incyte Corp. (INCY) stock fell by 2.32% to $102.04 on Monday, marking its second consecutive day of losses. This underperformance occurred during a general market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.

**3. Responsive Playbooks and the INCY Inflection**
- Source: Stock Traders Daily | 20251129T034000 | Bullish | Relevance: 98%
- This article from Stock Traders Daily analyzes Incyte Corporation (NASDAQ: INCY), highlighting a near-term strong sentiment that could lead to a long-term positive bias. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The analysis indicates elevated downside risk due to a lack of additional long-term support signals despite prevailing positive sentiment.

**4. Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention**
- Source: MyChesCo | 20251201T005122 | Bullish | Relevance: 98%
- Incyte Corp. (NASDAQ: INCY) will present at two major healthcare investor conferences in early December to discuss pipeline updates and strategic priorities. The biopharmaceutical company aims to highlight its late-stage programs, regulatory milestones, and market opportunities in oncology and autoimmune disease. These presentations are anticipated to draw significant market attention as Incyte navigates a competitive landscape to sustain long-term growth.

**5. Incyte appoints Richard Hoffman as executive VP and general counsel By Investing.com**
- Source: Investing.com South Africa | 20251201T150800 | Bullish | Relevance: 98%
- Incyte has appointed Richard Hoffman as Executive Vice President and General Counsel, effective immediately. Hoffman brings over 20 years of experience to the role, having previously been a Partner in Goodwin’s Life Sciences group. The biopharmaceutical company, which has seen its stock surge over 60% in the past six months and reported strong financial performance, expects him to oversee legal and compliance departments.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.7% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.3 |
| Current P/E | 14.9 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 5.3% to -3.4% (-8.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.4pp (needs >4.0% for momentum thesis). Underperforming sector by 4.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.34x) but short-term weakness (below SMA20). MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.40% (CS: 16) | Weak |
| RSI_14 | 53.7 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 1.085x | Above |
| vs SMA200 | 1.343x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $102.04
- **Stop Loss:** $95.58 (6.3% risk)
- **Target:** $114.96 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 116
- **Position Value:** $11,836.64
- **Portfolio %:** 11.84%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*